Cytokinetics Stock Alpha and Beta Analysis
| CYTK Stock | USD 43.10 0.35 0.81% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cytokinetics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cytokinetics over a specified time horizon. Remember, high Cytokinetics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cytokinetics' market risk premium analysis include:
Beta 0.34 | Alpha (0.17) | Risk 3.24 | Sharpe Ratio (0.04) | Expected Return (0.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cytokinetics |
Cytokinetics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cytokinetics market risk premium is the additional return an investor will receive from holding Cytokinetics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cytokinetics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cytokinetics' performance over market.| α | -0.17 | β | 0.34 |
Cytokinetics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cytokinetics' Buy-and-hold return. Our buy-and-hold chart shows how Cytokinetics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cytokinetics Market Price Analysis
Market price analysis indicators help investors to evaluate how Cytokinetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cytokinetics shares will generate the highest return on investment. By understating and applying Cytokinetics stock market price indicators, traders can identify Cytokinetics position entry and exit signals to maximize returns.
Cytokinetics Return and Market Media
The median price of Cytokinetics for the period between Fri, Dec 20, 2024 and Thu, Mar 20, 2025 is 46.87 with a coefficient of variation of 5.44. The daily time series for the period is distributed with a sample standard deviation of 2.54, arithmetic mean of 46.72, and mean deviation of 2.09. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Wierenga Wendall of 127 shares of Cytokinetics at 48.93 subject to Rule 16b-3 | 01/02/2025 |
2 | Acquisition by Malik Fady Ibraham of 5300 shares of Cytokinetics at 7.96 subject to Rule 16b-3 | 01/17/2025 |
3 | Disposition of 1536 shares by Sung Lee of Cytokinetics at 51.51 subject to Rule 16b-3 | 01/24/2025 |
4 | Acquisition by Robert Blum of 5000 shares of Cytokinetics at 6.67 subject to Rule 16b-3 | 01/31/2025 |
5 | Insider Trading | 02/10/2025 |
6 | Cytokinetics Inc Announces Upcoming Fourth Quarter Results and Conference Call | 02/13/2025 |
7 | Disposition of 2000 shares by Malik Fady Ibraham of Cytokinetics at 10.6 subject to Rule 16b-3 | 02/18/2025 |
8 | Disposition of 10092 shares by Henderson John T of Cytokinetics at 7.37 subject to Rule 16b-3 | 02/24/2025 |
9 | Cytokinetics Q4 2024 Earnings Preview | 02/26/2025 |
10 | Cytokinetics Inc Q4 2024 Earnings Call Highlights Revenue Surge Amidst Rising Expenses | 02/28/2025 |
11 | Disposition of 8743 shares by Robert Blum of Cytokinetics at 42.88 subject to Rule 16b-3 | 03/03/2025 |
12 | Insider Sell Alert Fady Malik Sells 2,000 Shares of Cytokinetics Inc | 03/04/2025 |
13 | Revenue Downgrade Heres What Analysts Forecast For Cytokinetics, Incorporated | 03/05/2025 |
14 | Insider Sell Alert Fady Malik Sells Shares of Cytokinetics Inc | 03/06/2025 |
15 | Acquisition by Malik Fady Ibraham of 2000 shares of Cytokinetics at 10.6 subject to Rule 16b-3 | 03/07/2025 |
16 | The essential biotech news stories of the day | 03/10/2025 |
17 | Disposition of 100 shares by Andrew Callos of Cytokinetics at 45.0 subject to Rule 16b-3 | 03/14/2025 |
18 | Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session Expo | 03/17/2025 |
19 | Disposition of 200 shares by Malik Fady Ibraham of Cytokinetics subject to Rule 16b-3 | 03/19/2025 |
About Cytokinetics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cytokinetics or other stocks. Alpha measures the amount that position in Cytokinetics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | |
| Interest Debt Per Share | 8.91 | 8.43 | 6.98 |
| Revenue Per Share | 1.05 | 0.078 | 0.16 |
Cytokinetics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cytokinetics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytokinetics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cytokinetics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cytokinetics. Please utilize our Beneish M Score to check the likelihood of Cytokinetics' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cytokinetics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Cytokinetics Backtesting, Cytokinetics Valuation, Cytokinetics Correlation, Cytokinetics Hype Analysis, Cytokinetics Volatility, Cytokinetics History and analyze Cytokinetics Performance. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Cytokinetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.